Overview

A class action lawsuit has been filed against Bath & Body Works, Inc., (“Bath & Body Works,” or the “Company”) (NYSE : BBWI) and certain of the Company’s senior executive officers (collectively, “Defendants”) alleging violations of federal securities laws. The Bath & Body Works lawsuit is brought on behalf of all persons and entities who purchased or otherwise acquired Bath & Body Works securities between June 4, 2024, and November 19, 2025, both dates inclusive (the “Class Period”). Investors have until March 13, 2026, to seek appointment as lead plaintiff of the Bath & Body Works class action lawsuit.

Bath & Body Works is a specialty retailer of home fragrance and body care products. Starting in fiscal year 2024, Bath & Body Works increasingly explored product categories, or “adjacencies,” beyond its core business. The Company’s four key adjacencies include products for men, lips, hair, and laundry. Throughout 2024 and 2025, the Company touted these adjacencies as drivers of growth.

The lawsuit alleges Defendants made false and/or misleading statements, and failed to disclose material adverse facts about the Company’s business, operations, and prospects. The complaint specifically alleges the Company failed to disclose to investors: (1) the Company’s strategy of pursuing “adjacencies, collaborations and promotions” was not growing the customer base or delivering the level of growth in net sales touted; (2) as the Company’s strategy of “adjacencies, collaborations and promotions” faltered, the Company relied on brand collaborations “to carry quarters” and obfuscate otherwise weak underlying financial results; and (3) as a result, the Company was unlikely to meet its own previously issued financial guidance.

The truth began to be revealed on August 28, 2025, when Bath & Body Works released disappointing second quarter 2025 financial results and slashed full year guidance. On this news, Bath & Body Works’ stock price fell $2.18, or nearly 7%, to close at $29.36 per share on August 28, 2025.

Then, on November 20, 2025, Bath & Body Works announced disappointing financial results for the third quarter of 2025 and that the Company was cutting guidance. In an investor presentation published the same day, the Company announced a new business strategy and admitted its strategy of “adjacencies, collaborations and promotions” had “not grown our total customer base.” The Company also offered a “diagnosis” of its underperformance, including that the focus on adjacencies had “reduced focus on investing in our core categories;” that collaborations “have been used to carry quarters;” and that the Company had become “overly reliant on deeper and more frequent promotions to drive growth.” On this news, Bath & Body Works’ stock price fell $5.22, or nearly 25%, to close at $15.82 per share on November 20, 2025.

*            *            *

If you purchased or otherwise acquired Bath & Body Works securities between June 4, 2024, and November 19, 2025, and you wish to serve as lead plaintiff in this lawsuit, you are encouraged to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt attorneys Brian O’Mara or Hani Farah by calling (888) 287-9005 or at investors@dicellolevitt.com. 

The deadline to apply to the Court to serve as a lead plaintiff in the Bath & Body Works lawsuit is March 13, 2026.